Discovery and Molecular Mechanisms of New Anticancer Drugs
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pharmacology".
Deadline for manuscript submissions: 30 August 2024 | Viewed by 1379
Special Issue Editors
Interests: bioactive natural compounds; secondary metabolites; chromatographic techniques; spectroscopic techniques; natural compounds
Special Issues, Collections and Topics in MDPI journals
Interests: natural and synthetic bioactive compounds; mechanisms of anticancer activity; nuclear receptor modulators; nanoparticle-based drug carriers; metronomic anticancer therapy; combination anticancer therapy; high-performance liquid chromatography of bioactive compounds
Special Issue Information
Dear Colleagues,
Despite huge progress in cancer treatment, this disease continues to be a global problem and challenge for scientists to improve the success of the therapy. In addition to the classical cytostatic compounds, a number of new molecules were developed as drugs for precision medicine that targeted selectively cancer cells: antibodies, antibody–drug conjugates, nuclear receptor modulators, cancer protein inhibitors, etc. Nanoparticles, loaded with anticancer antibodies, protein inhibitors or cytostatic compounds, offer alternative approaches to increase the efficiency of bioactive molecules and reduce the toxicity of poorly water-soluble chemotherapeutic compounds. The development of knowledge on the mechanisms of the antiproliferative activity and DNA repair mechanisms is an important step in the treatment of cancer.
This Special Issue is devoted to the discovery of new anticancer drugs along with elucidation of their mechanisms of activity. The identification of new natural or synthetic molecules, including cytostatic compounds, nuclear receptor or oncoprotein modulators, antibodies, etc., with the study of their cancer inhibition mechanisms and drug–protein interactions can contribute to the present Special Issue. Nanotechnology-based new drug delivery systems that target cancer cells are also of interest. Clinical trials are not suitable for this Special Issue; however, preclinical and clinical results with the analysis of the mechanisms of anticancer treatment using biomolecular experiments are also welcome.
Potential topics include, but are not limited to, the following:
- Mechanisms of activity of new natural or synthetic antiproliferative compounds;
- Oncoprotein inhibitors and oncogene targeted therapies;
- Nuclear receptor modulators;
- Cancer-cell-targeted antibodies, antibody–drug conjugates;
- Anticancer drug carriers, nanoparticle-based drug delivery systems;
- DNA repair mechanisms, regulation of gene expression in cancer;
- Anticancer drug design and drug-protein interactions;
- Preclinical and clinical results with biomolecular experiments about the mechanisms of activity of anticancer therapy.
Dr. Ana M. L. Seca
Dr. Diana I. Ivanova
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- anticancer drugs
- drug design
- drug delivery systems
